[go: up one dir, main page]

CN101035540A - 治疗呼吸疾病的包含苯并嗪的药物组合 - Google Patents

治疗呼吸疾病的包含苯并嗪的药物组合 Download PDF

Info

Publication number
CN101035540A
CN101035540A CNA2005800126210A CN200580012621A CN101035540A CN 101035540 A CN101035540 A CN 101035540A CN A2005800126210 A CNA2005800126210 A CN A2005800126210A CN 200580012621 A CN200580012621 A CN 200580012621A CN 101035540 A CN101035540 A CN 101035540A
Authority
CN
China
Prior art keywords
amino
phenyl
quinazoline
chloro
fluoro
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA2005800126210A
Other languages
English (en)
Chinese (zh)
Inventor
蒂里·鲍索
英戈·科纳茨基
萨拜因·佩斯特尔
安德烈亚斯·肖纳普
克里斯托弗·霍恩克
菲利普·勒斯滕伯格
克劳斯·鲁道夫
迈克尔·P·皮珀
米歇尔·佩莱特
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Boehringer Ingelheim International GmbH
Original Assignee
Boehringer Ingelheim International GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim International GmbH filed Critical Boehringer Ingelheim International GmbH
Publication of CN101035540A publication Critical patent/CN101035540A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/538—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with carbocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Pulmonology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CNA2005800126210A 2004-04-22 2005-04-18 治疗呼吸疾病的包含苯并嗪的药物组合 Pending CN101035540A (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
DE102004019540.4 2004-04-22
DE102004019540A DE102004019540A1 (de) 2004-04-22 2004-04-22 Neue Arzneimittelkombinationen zur Behandlung von Atemwegserkrankungen
DE102004052987.6 2004-11-03
EP05002496.7 2005-02-07

Publications (1)

Publication Number Publication Date
CN101035540A true CN101035540A (zh) 2007-09-12

Family

ID=35456100

Family Applications (1)

Application Number Title Priority Date Filing Date
CNA2005800126210A Pending CN101035540A (zh) 2004-04-22 2005-04-18 治疗呼吸疾病的包含苯并嗪的药物组合

Country Status (3)

Country Link
CN (1) CN101035540A (ru)
DE (1) DE102004019540A1 (ru)
UA (1) UA85708C2 (ru)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN118903009A (zh) * 2024-10-11 2024-11-08 江苏长泰药业股份有限公司 一种调节呼吸道微生态的丙酮酸钠气雾剂及其制备方法和应用

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7407955B2 (en) 2002-08-21 2008-08-05 Boehringer Ingelheim Pharma Gmbh & Co., Kg 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
US7056916B2 (en) 2002-11-15 2006-06-06 Boehringer Ingelheim Pharma Gmbh & Co. Kg Medicaments for the treatment of chronic obstructive pulmonary disease
US7501426B2 (en) 2004-02-18 2009-03-10 Boehringer Ingelheim International Gmbh 8-[3-amino-piperidin-1-yl]-xanthines, their preparation and their use as pharmaceutical compositions
US7220742B2 (en) 2004-05-14 2007-05-22 Boehringer Ingelheim International Gmbh Enantiomerically pure beta agonists, process for the manufacture thereof and use thereof as medicaments
DE102004054054A1 (de) 2004-11-05 2006-05-11 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verfahren zur Herstellung chiraler 8-(3-Amino-piperidin-1-yl)-xanthine
DE102005035891A1 (de) 2005-07-30 2007-02-08 Boehringer Ingelheim Pharma Gmbh & Co. Kg 8-(3-Amino-piperidin-1-yl)-xanthine, deren Herstellung und deren Verwendung als Arzneimittel
WO2007020227A1 (de) 2005-08-15 2007-02-22 Boehringer Ingelheim International Gmbh Verfahren zur herstellung von betamimetika
EP1986644A1 (de) * 2006-02-16 2008-11-05 Boehringer Ingelheim International GmbH Arzneimittelkombinationen zur behandlung von atemwegserkrankungen
PE20080251A1 (es) 2006-05-04 2008-04-25 Boehringer Ingelheim Int Usos de inhibidores de dpp iv
NZ573360A (en) 2006-05-04 2012-08-31 Boehringer Ingelheim Int Polymorphic forms of 1-[(4-methyl-quinazolin-2-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-(3-(R)-amino-piperidin-1-yl)-xanthine
EP1852108A1 (en) 2006-05-04 2007-11-07 Boehringer Ingelheim Pharma GmbH & Co.KG DPP IV inhibitor formulations
UY30542A1 (es) * 2006-08-18 2008-03-31 Boehringer Ingelheim Int Formulacion de aerosol para la inhalacion de agonistas beta
PE20140960A1 (es) 2008-04-03 2014-08-15 Boehringer Ingelheim Int Formulaciones que comprenden un inhibidor de dpp4
KR20200118243A (ko) 2008-08-06 2020-10-14 베링거 인겔하임 인터내셔날 게엠베하 메트포르민 요법이 부적합한 환자에서의 당뇨병 치료
UY32030A (es) 2008-08-06 2010-03-26 Boehringer Ingelheim Int "tratamiento para diabetes en pacientes inapropiados para terapia con metformina"
AU2009290911A1 (en) 2008-09-10 2010-03-18 Boehringer Ingelheim International Gmbh Combination therapy for the treatment of diabetes and related conditions
US20200155558A1 (en) 2018-11-20 2020-05-21 Boehringer Ingelheim International Gmbh Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug
MX2011006713A (es) 2008-12-23 2011-07-13 Boehringer Ingelheim Int Formas salinas de compuesto organico.
AR074990A1 (es) 2009-01-07 2011-03-02 Boehringer Ingelheim Int Tratamiento de diabetes en pacientes con un control glucemico inadecuado a pesar de la terapia con metformina
AU2010323068B2 (en) 2009-11-27 2015-09-03 Boehringer Ingelheim International Gmbh Treatment of genotyped diabetic patients with DPP-IV inhibitors such as linagliptin
KR101927068B1 (ko) 2010-05-05 2018-12-10 베링거 인겔하임 인터내셔날 게엠베하 체중 감소 치료에 후속하는 dpp-4 억제제에 의한 순차적 병용 요법
WO2011161161A1 (en) 2010-06-24 2011-12-29 Boehringer Ingelheim International Gmbh Diabetes therapy
US9034883B2 (en) 2010-11-15 2015-05-19 Boehringer Ingelheim International Gmbh Vasoprotective and cardioprotective antidiabetic therapy
WO2013010964A1 (en) 2011-07-15 2013-01-24 Boehringer Ingelheim International Gmbh Substituted quinazolines, the preparation thereof and the use thereof in pharmaceutical compositions
US9555001B2 (en) 2012-03-07 2017-01-31 Boehringer Ingelheim International Gmbh Pharmaceutical composition and uses thereof
EP2849754B1 (en) 2012-05-14 2022-09-14 Boehringer Ingelheim International GmbH Linagliptin, a xanthine derivative as dpp-4 inhibitor, for use in the treatment of sirs and/or sepsis
EP2849755A1 (en) 2012-05-14 2015-03-25 Boehringer Ingelheim International GmbH A xanthine derivative as dpp -4 inhibitor for use in the treatment of podocytes related disorders and/or nephrotic syndrome
WO2013174767A1 (en) 2012-05-24 2013-11-28 Boehringer Ingelheim International Gmbh A xanthine derivative as dpp -4 inhibitor for use in modifying food intake and regulating food preference
ES2950384T3 (es) 2014-02-28 2023-10-09 Boehringer Ingelheim Int Uso médico de un inhibidor de DPP-4
JP2019517542A (ja) 2016-06-10 2019-06-24 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング リナグリプチンおよびメトホルミンの組合せ

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN118903009A (zh) * 2024-10-11 2024-11-08 江苏长泰药业股份有限公司 一种调节呼吸道微生态的丙酮酸钠气雾剂及其制备方法和应用
CN118903009B (zh) * 2024-10-11 2025-01-21 江苏长泰药业股份有限公司 一种调节呼吸道微生态的丙酮酸钠气雾剂及其制备方法和应用

Also Published As

Publication number Publication date
UA85708C2 (ru) 2009-02-25
DE102004019540A1 (de) 2005-11-10

Similar Documents

Publication Publication Date Title
CN101035540A (zh) 治疗呼吸疾病的包含苯并嗪的药物组合
US20050239778A1 (en) Novel medicament combinations for the treatment of respiratory diseases
CN1713914A (zh) 用于治疗慢性阻塞性肺病的新药物
CN1906180A (zh) 新的长效β－2－激动剂及其作为药物的用途
CA2559699C (en) Pharmaceutical combinations containing benzoxazine for treating respiratory diseases
CN1728990A (zh) 腺苷A2a受体拮抗剂的应用
JP2007537196A (ja) 新規の鏡像異性的に純粋なベータ−作用薬、その製造方法および製剤の形体におけるその使用
CN1946406A (zh) 治疗呼吸道疾病的苯并噁嗪
CN1802157A (zh) 用于肺吸入的包含阿扑吗啡的药物组合物
US20050267106A1 (en) New enentiomerically pure beta agonists, process for the manufacture thereof and use thereof as medicaments
CN101039937A (zh) 在呼吸系统疾病的治疗中用作β模拟剂的杂芳基化合物
US20090181961A1 (en) Novel medicaments for the treatment of respiratory diseases
US20080051392A1 (en) Pharmaceutical combinations for the treatment of respiratory diseases
CN101056640A (zh) 用于吸入β－拮抗剂的气溶胶制剂
CN1633305A (zh) 基于抗胆碱能剂和egfr激酶抑制剂的新颖药物组合物
HK1107779A (en) Pharmaceutical combinations containing benzoxazine for treating respiratory diseases
CN1665539A (zh) 基于新抗胆碱能剂及egfr激酶抑制剂的新颖药物组合物
CN1652822A (zh) 用于治疗气道病症的可逆质子泵抑制剂和气道治疗剂的新组合
US20070037781A1 (en) Novel combinations of medicaments for the treatment of respiratory diseases containing long-acting beta-agonists and at least one additional active ingredient
US20100297028A1 (en) Medicament combinations for the treatment of respiratory diseases
HK1101501A (en) Benzoxazine for treating respiratory tract diseases
US20090324510A1 (en) Drug combinations for the treatment of respiratory tract diseases
HK1083760A (en) Novel medicaments for the treatment of chronic obstructive pulmonary diseases
HK1113467A (en) Aerosol formulation for inhalation of beta agonists
CN1845911A (zh) 稠环化合物及其应用

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1107779

Country of ref document: HK

C12 Rejection of a patent application after its publication
RJ01 Rejection of invention patent application after publication

Application publication date: 20070912

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1107779

Country of ref document: HK